Skip to main content
. 2016 Sep 1;23(9):1055–1066. doi: 10.5551/jat.34660

Table 1. Baseline Clinical Characteristics.

Variable Non-HDL-Cholesterol (mg/dl)
≦ 140 n = 38 141–169 n = 42 ≧ 170 n = 39 p value
Age years 70.3 ± 8.8 67.0 ± 8.9 62.9 ± 11.6 0.006
Men 33 (86.8%) 33 (78.6%) 33 (84.6%) 0.62
Body mass index (kg/mm2) 23.5 ± 2.8 23.9 ± 2.8 25.9 ± 4.3 0.004
Diabetes Mellitus 14 (36.8%) 15 (35.7%) 21 (53.8%) 0.19
Hypertension 26 (68.4%) 25 (59.5%) 24 (61.5%) 0.69
Treatment allocation
    Pitavastatin 21 (55.3%) 19 (45.2%) 18 (46.2%) 0.62
    Pravastatin 17 (44.7%) 23 (54.8%) 21 (53.8%)
Stable angina pectoris 30 (78.9%) 31 (73.8%) 22 (56.4%) 0.077
Unstable angina pectoris 8 (21.1%) 11 (26.2%) 17 (43.6%)
Target vessel
    Left anterior descending 23 (60.5%) 22 (52.4%) 22 (56.4%) 0.72
    Left circumflex 1 (2.6%) 1 (2.4%) 3 (7.7%)
    Right 14 (36.8%) 19 (45.2%) 14 (35.9%)
Type of stent
    Bare metal stent 5 (13.2%) 10 (23.8%) 5 (12.8%) 0.34
    Drug-eluting stent 33 (86.8%) 32 (76.2%) 34 (87.2%)
Medications
    Aspirin 37 (97.4%) 41 (97.6%) 39 (100%) 0.77
    Thienopyridine 37 (97.4%) 41 (97.6%) 38 (97.4%) 0.99
    ACE-I or ARB 23 (60.5%) 18 (42.9%) 20 (51.3%) 0.29
    β-blocker 5 (13.2%) 2 (4.8%) 6 (15.4%) 0.25
    Calcium channel blocker 23 (60.5%) 20 (47.6%) 17 (43.6%) 0.30
Follow-up duration (days) 236 ± 37 221 ± 35 225 ± 37 0.15

Values are means ± SDs or numbers (percentages); HDL, high-density lipoprotein; ACE-I indicates, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker